|
AGGRASTAT
AGGRASTAT, a cardiovascular product, is FDA approved and is currently being sold by Medicure in the United States.
TARDOXAL
Medicure is currently enrolling patients in a phase II clinical trial. TARDOXALTM is being tested for unmet needs in the neurological field.
LICENSING OPPORTUNITIES
Medicure is seeking a partner with an established cardiovascular franchise to support ongoing worldwide clinical antithrombotic development programs.
| |
|
|
